Nanofiber Solutions, LLC appears in FDA 510(k) records as the applicant for BioCharge, a bioresorbable autobiologic matrix intended for use with suture anchors in rotator cuff repair. The company's own website describes a broader platform of electrospun nanofiber scaffolds for cell culture and regenerative medicine research. The two threads are documented separately: FDA clearance records establish the regulatory identity of BioCharge, while the manufacturer's published pages describe the scaffold product line. The company's own timeline lists earlier FDA clearances without naming the devices involved. [1][2][4][5]
BioCharge and its 510(k) record
FDA record K263682 names Nanofiber Solutions, LLC of Dublin, Ohio as applicant for a device called BioCharge, received October 7, 2026 and decided November 5, 2026 as substantially equivalent under product code OWW, regulation 878.3300, with the advisory committee described as general and plastic surgery. The same record lists the device name as an absorbable surgical mesh for orthopedic reinforcement of tendon. A separate clearance, K241912, was received and decided in July 2024 under regulation 888.3030 and product code MAI, with the orthopedic review panel. [1][2][3]
The K241912 clearance letter describes the device as gamma-sterilized and single use, and states that the design was updated to include a pre-built pathway for suture passage, with no other changes to technological characteristics. The FDA database entry for that submission records a substantially equivalent decision dated July 29, 2024, a special review type, and no third-party review. [2][3]
Documented product form and components
Atreon Orthopedics' published BioCharge brochure describes a bioresorbable autobiologic matrix for the bursal side of the rotator cuff, with an integrated suture tunnel and no secondary fixation, and states the device is intended for use with suture anchors in rotator cuff repair, referencing clearance K241912. The brochure lists a size of 2cm by 1.2 cm at 1.7mm thickness and states the device contains no human or animal sourced materials. [6]
The BioCharge instructions for use give the indication as use in conjunction with suture anchors for reattachment of tendon to bone in rotator cuff repairs, describe the device as a bioresorbable wick accessory, and list a single reference size, BC-2012, at 20mm by 12mm. The document includes a compatibility table naming specific suture anchors from Arthrex, including SwiveLock C and Corkscrew FT models. [7]
Nanofiber scaffold products for cell culture
Nanofiber Solutions' own product pages describe patent-pending electrospun fiber multiwell plates for high-throughput cell culture, cancer research, stem cell work and regenerative medicine, using aligned (NanoAligned) or randomly oriented (NanoECM) polymer nanofibers integrated into standard multiwell dishes. Standard products use polycaprolactone nanofibers, and the company states it offers custom 3D nanofiber scaffolds for bioreactor scale-up and regenerative medicine, made of synthetic or natural nanofiber polymers with optional blends or surface chemistry modifications. [8]
The company homepage states that Nanofiber Solutions designs and manufactures three-dimensional nanofiber scaffolds intended to mimic the extracellular matrix, and that the platform is used to build structures for several markets. The company page describes it as a regenerative medicine company developing implants for soft tissue and organ repair and regeneration, and its timeline lists a second FDA clearance of an NFS product in 2019, a move to a Dublin facility in 2021, and the formation of Nanos in 2026, without naming the cleared devices. [4][5]
What the record does and does not establish
The linked collection contains one 510(k) record, K263682, decided substantially equivalent, and the record sample reflects that single entry; these counts describe the linked filings only and not total clearances, sales or safety performance. The K241912 letter and database entry document an earlier clearance for BioCharge under a different regulation number and product code, and the company timeline refers to earlier clearances without identifying them. [1][2][3][4]
Atreon Orthopedics publishes the BioCharge brochure and instructions for use, and those documents carry the Atreon name and describe the device's intended use; the FDA records name Nanofiber Solutions as applicant. The relationship between the two organizations is not described in the linked sources, and no parent, brand ownership or commercial distribution arrangement is verified there. Headquarters, customers and clinical performance are not established by these documents. [1][6][7][9]

